Abstract: This oscillator comprises: a source generating an incident optical wave at a pulsation frequency ?; an optomechanical resonator, having optical resonances at the pulsation frequency ? and mechanical resonances at a frequency f1 and generating, from the incident optical wave, emergent optical waves at the pulsation frequencies ? and ??2?f1, and an acoustic wave at frequency f1; and, a photodiode delivering a useful signal at frequency f1 from the emergent waves. This oscillator further comprises: an acoustic propagation means for propagating the acoustic wave over a distance in order to produce a delayed acoustic wave; a means for converting the delayed acoustic wave into a delay signal at the frequency f1; and, a control loop, processing the delay signal in order to obtain a control signal applied to the source.

Abstract: This oscillator comprises: a source generating an incident optical wave at a pulsation frequency ?; an optomechanical resonator, having optical resonances at the pulsation frequency ? and mechanical resonances at a frequency f1 and generating, from the incident optical wave, emergent optical waves at the pulsation frequencies ? and ??2?f1, and an acoustic wave at frequency f1; and, a photodiode delivering a useful signal at frequency f1 from the emergent waves. This oscillator further comprises: an acoustic propagation means for propagating the acoustic wave over a distance in order to produce a delayed acoustic wave; a means for converting the delayed acoustic wave into a delay signal at the frequency f1; and, a control loop, processing the delay signal in order to obtain a control signal applied to the source.

Abstract: A process for manufacturing a process for manufacturing a part made of a magnesium alloy is disclosed. The process includes a step of forging a block of the alloy followed by a heat treatment. The alloy is a casting alloy based on 85% magnesium, and containing, by weight: 0.2 to 1.3% zinc; 2 to 4.5% neodymium; 0.2 to 7.0% rare-earth metal with an atomic number from 62 to 71; 0.2 to 1% zirconium. The forging is carried out at a temperature above 400° C. In particular the temperature is set between 420 and 430° C. and the forging step comprises a plastic deformation carried out at a slow rate. The process allows one to produce parts such as elements of casing for aeronautical machines, operating at a temperature of around 200° C. and having good aging properties.

Abstract: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+HLA, or comprises a doubly negative CD56?/CD15? cell type or may comprise more minority CD10+, Stro-1+ and CD 117+ cell types.

Abstract: The present invention relates to a process for manufacturing a process for manufacturing a part made of a magnesium alloy, comprising a step of forging a block of said alloy followed by a heat treatment, characterized in that the alloy is a casting alloy based on 85% magnesium, and containing, by weight: 0.2 to 1.3% zinc; 2 to 4.5% neodymium; 0.2 to 7.0% rare-earth metal with an atomic weight from 62 to 71; 0.2 to 1% zirconium, and in that the forging is carried out at a temperature above 400° C. In particular the temperature is set between 420 and 430° C. and the forging step comprises a plastic deformation carried out at a slow rate. The process allows to produce parts such as elements of casing for aeronautical machines, operating at a temperature of around 200° C. and having good aging properties.

Abstract: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+ HLA, or comprises a doubly negative CD56?/CD15? cell type or may comprise more minority CD10+, Stro-1+ and CD117+ cell types.

Abstract: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+ HLA, or comprises a doubly negative CD56−/CD15− cell type or may comprise more minority CD10+, Stro-1+ and CD117+ cell types.